Scrip is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

PANORAMA Helps Regeneron's Eylea Even Score With Roche's Lucentis

Executive Summary

Phase III PANORAMA looks good, so far, for Regeneron's Eylea in diabetic retinopathy without edema.

You may also be interested in...



Keeping Track: Resubmissions For Tlando And Twirla NDAs, And A BTD For Pomalyst

The latest drug development news and highlights from our US FDA Performance Tracker.

Regeneron Gets A Win With Eylea Approval In Diabetic Retinopathy

Regeneron's workhorse blockbuster Eylea has scored another indication for diabetic retinopathy, as the company braces for new competition from Novartis later this year.

Regeneron Tries To Put Focus On PD-1 Program, Not Sluggish Autoimmune Sales

Regeneron promised big things for PD-1 inhibitor cemiplimab during its first quarter earnings call, including studies to test its potential in lung cancer compared to Merck's Keytruda. It hopes to launch the antibody in a smaller indication later this year.

Related Content

Topics

Related Companies

UsernamePublicRestriction

Register

ID034708

Ask The Analyst

Please Note: Click here for more information on the Ask the Analyst service.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel